References
- Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J. 2008; 14:428–34.
- Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009; 14:645–56.
- Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871–90.
- Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. In: van Roy F, editor. The molecular biology of cadherins. San Diego: Academic Press; 2013, p. 317–36. (series. Prog Mol Biol Transl Sci., vol. 116).
- Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-cadherin and N-cadherin switch in epithelial-tomesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019; 8:1118. doi: 10.3390/cells8101118
- Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015; 21:1253–61.
- Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014; 74:1651–60.
- Peng F, Li T-T, Wang K-L, Xiao G-Q, Wang J-H, Zhao H-D, et al. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2017; 8:e2569. doi: 10.1038/cddis.2016.438
- Peng W, Fan H. Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma. Biomed Pharmacother. 2015; 72:113–8.
- Ma P, Xu T, Huang M, Shu Y. Increased expression of lncRNA PANDAR predicts a poor prognosis in gastric cancer. Biomed Pharmacother. 2016; 78:172–6.
- Sang Y, Tang J, Li S, Li L, Tang X-F, Cheng C, et al. lncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16INK4A expression. Sci Rep. 2016; 6:22366. doi: 10.1038/srep22366
- Lu M, Liu Z, Li B, Wang G, Li D, Zhu Y. The high expression of long non-coding RNA PANDAR indicates a poor prognosis for colorectal cancer and promotes metastasis by EMT pathway. J Cancer Res Clin Oncol. 2017; 143:71–81.
- Renganathan A, Kresoja-Rakic J, Echeverry N, Ziltener G, Vrugt B, Opitz I, et al. GAS5 long non-coding RNA in malignant pleural mesothelioma. Mol Cancer. 2014; 13:119. doi: 10.1186/1476-4598-13-119
- Azzalin CM, Lingner J. Telomere functions grounding on TERRA firma. Trends Cell Biol. 2015; 25:29–36.
- Hung C-L, Wang L-Y, Yu Y-L, Chen H-W, Srivastava S, Petrovics G, Kung H-J. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A. 2014; 111:18697–702.
- Yuan S-X, Yang F, Yang Y, Tao Q-F, Zhang J, Huang G, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology. 2012; 56:2231–41.
- Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015; 27:370–81.
- Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013; 108:2419–25.
- Han L, Zhang E-b, Yin D-d, Kong R, Xu T-p, Chen W-m, et al. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 2015; 6:e1665. doi: 10.1038/cddis.2015.30
- Zhan Y, Lin J, Liu Y, Chen M, Chen X, Zhuang C, et al. Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer. J Exp Clin Cancer Res. 2016; 35:83. doi: 10.1186/s13046-016-0354-7